tbuckley/cabot-search huggingface dataset:
Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial
Authors: J J Shah, L Feng, S K Thomas, Z Berkova, D M Weber, M Wang, M H Qazilbash, R E Champlin, T R Mendoza, C Cleeland, R Z Orlowski
Journal: Blood Cancer Journal (2016)

Abstract The safety and efficacy of siltuximab (CNTO 328) was tested in combination with lenalidomide, bortezomib and dexamethasone (RVD) in patients with newly-diagnosed, previously untreated symptomatic multiple myeloma. Fourteen patients were enrolled in the study, eleven of whom qualified to receive therapy. A majority of patients (81.8%) completed the minimal number or more of the four required cycles, while two patients completed only three cycles. The maximum tolerated dose (MTD) of siltuximab with RVD was dose level −1 (siltuximab: 8.3 mg/kg; bortezomib: 1.3 mg/m 2 ; lenalidomide: 25 mg; dexamethasone: 20 mg). Serious adverse events were grade 3 pneumonia and grade 4 thrombocytopenia, and no deaths occurred during the study or with follow-up (median follow-up 28.1 months). An overall response rate, after 3–4 cycles of therapy, of 90.9% (95% confidence interval (CI): 58.7%, 99.8%) (9.1% complete response (95% CI: 0.2%, 41.3%), 45.5% very good partial response (95% CI: 16.7%, 76.6%) and 36.4% partial response (95% CI: 10.9%, 69.2%)) was seen. Two patients withdrew consent, and nine patients (81.8%) opted for autologous stem cell transplantation.
원저 : 비대상성 알콜성 및 바이러스성 간경변증사이의 혈소판 감소증 비교
Authors: 구은실(Eun Sil Koo), 김병익(Byung Ik Kim), 김시영(Si Young Kim), 조용균(Yong Kyun Cho), 김창섭(Chang Sub Kim), 박창영(Chang Young Park), 손정일(Chong Il Sohn), 전우규(Woo Kyu Jeon), 정을순(Eul Soon Jung), 금동극(Dong Kug Kum), 이영래(Young Rae Lee), 이화영(Hwa Young Lee), 이상종(Sang Jong Lee)
Journal: Clinical and Molecular Hepatology (2000)

Background/Aims: Thrombocytopenia is frequently found among patients with chronic liver disease, and its mechanism, especially among patients with decompensated liver cirrhosis had not been established. Therefore to elucidate the mechanism of thrombocytopenia, the relationship between thrombocytopenia and severity of hepatic dysfunction, splenomegaly was measured. We measured the peripheral blood components with splenic volume obtained from a computerized tomography of decompensated liver cirrhosis patients. Methods: We studied 103 patients who had been diagnosed with decompensated liver cirrhosis with esophageal varices and ascites from January 1982 to August 1999. We checked their counts of platelets, albumin, bilirubin, splenic volume, degree of esophageal varices, hepatic encephalopathy and ascites by retrograde methods. Results: In viral liver cirrhosis, thrombocytopenia and splenomegaly correlated well with disease severity but they didn't in alcoholic cirrhosis. Of special note, the platelet count was significantly lower and the splenic volume was larger in the Child C of viral cirrhosis patients group than in the alcoholic group(p<0.05). Conclusion: When we compared decompensated alcoholic with viral liver cirrhosis patients, the degrees of thrombocytopenia and splenomegaly were much less in the former group. The factors for this phenomena are Splenic Pooling theory, Platelet-associated IgG, Thrombopoietin and Toxic Marrow. We suggest that splenomegaly is an important factor among these, but the mechanisms involved in the pathogenesis of this hematologic phenomena are not completely understood. Especially in alcoholic liver cirrhosis, many other factors may be involved, including the direct effect of alcohol to bone marrow, so further studies will be needed to establish whether a causal relationship exists.(Korean J Hepatol 2000;6:215-222)
Tarasoff: protective privilege versus public peril
Authors: H Gurevitz
Journal: American Journal of Psychiatry (1977)

The author reviews the decision made by the California Supreme Court in the case of Tarasoff v. the Regents of the University of California, et al., which stipulated that therapists must warn authorities specified by law as well as potential victims of possible dangerous actions of their patients. He states the basic points of the Northern California Psychiatric Society's amicus curiae brief on behalf of the university regents and discusses the issues raised by the Tarasoff decision vis--53a-vis the mental health profession and its dealings with potentially violent individuals.
Clinical modulation of doxorubicin resistance by the calmodulin-inhibitor, trifluoperazine: a phase I/II trial.
Authors: R L Miller, R M Bukowski, G T Budd, J Purvis, J K Weick, K Shepard, K K Midha, R Ganapathi
Journal: Journal of Clinical Oncology (1988)

Drug resistance to chemotherapy agents such as doxorubicin appears to be an important cause of therapeutic failure in cancer treatment. Based on preclinical information demonstrating that the phenothiazine calmodulin-inhibitor trifluoperazine can enhance retention and cytotoxicity of doxorubicin in resistant cells, a phase I/II trial of the combination was performed to determine the maximally tolerated dose (MTD) of trifluoperazine that could be administered with doxorubicin. Patients with intrinsic (no previous response) and acquired (previous response with relapse) doxorubicin resistance were eligible. Doxorubicin was administered as a 96-hour continuous infusion (60 mg/m2) on days 2 through 5. Trifluoperazine was administered in divided doses orally on days 1 through 6, with dose escalation from 20 to 100 mg/d. Thirty-six patients were evaluable. The MTD of trifluoperazine was 60 mg/d, with dose-limiting toxicity being extrapyramidal side effects. No alteration of doxorubicin toxicity was observed. Seven of the 36 patients responded (one complete response [CR], six partial responses [PR]), with seven of 21 patients having acquired resistance, and zero of 15 with intrinsic resistance demonstrating responses. Doxorubicin plasma levels were not affected by trifluoperazine, and the maximal trifluoperazine plasma levels achieved were 129.83 ng/mL. This trial demonstrates the combination of trifluoperazine and doxorubicin is well tolerated, and the schedule recommended for phase II trials is doxorubicin, 60 mg/m2 (continuous infusion) days 2 through 5, and trifluoperazine, 15 mg four times per day orally days 1 through 6. Continued investigation of this combination is indicated for patients with acquired doxorubicin resistance.
VAD-PECC regimen in the treatment of advanced-stage multiple myeloma.
Authors: M Delain, C Linassier, C Petitdidier, P Goupille, F Luthier, M Combe, M Reisenleiter, L Benboubker, J P Lamagnère, P Colombat
Journal: Journal of Clinical Oncology (1994)

PURPOSE This prospective study was undertaken to evaluate the efficacy of combination chemotherapy with alternating cycles of vincristine, doxorubicin, and dexamethasone (VAD) and prednisone, vindesine, carmustine, and cyclophosphamide (PECC) in poor-risk multiple myeloma (MM). PATIENTS AND METHODS Forty-four patients were previously untreated; 36 had been pretreated with an alkylating agent-containing regimen and had refractory or relapsed MM. All previously untreated patients had a high tumor burden at inclusion (stage III according to the Durie and Salmon classification). Logistic regression and the Cox proportional hazards models were used to assess the association between patient characteristics and response rate and survival, respectively. RESULTS The overall response rate was 68% for previously untreated patients, compared with 54% for previously treated patients (P = .16). The median survival time for all patients was 28 months: 53 months in previously untreated patients, and 18 months in previously treated patients. Univariate analysis showed that the predictive factors that had a significant affect on survival in the newly diagnosed patients were age, therapeutic response to VAD-PECC, low pretreatment Karnofsky score, high baseline serum beta 2-microglobulin (beta 2M) level, bone marrow impairment, and renal insufficiency at the start of treatment. When these parameters were used as continuous variables in multivariate analysis, three were found to correlate with survival: serum beta 2M, followed by therapeutic response and Karnofsky score. In the previously treated group, only Karnofsky score entered the Cox model. CONCLUSION These results indicate that combination VAD-PECC chemotherapy is an effective treatment that results in high response rates and long-term survival in advanced MM.
Generation and Characterization Of a Third Party GMP Grade Bank Of CMV Specific T-Cells For Adoptive Immunotherapy Of CMV Infections In Recipients Of HSCT From Cord Blood Or Seronegative Donors
Authors: Aisha N. Hasan, Ekaterina Doubrovina, Guenther Koehne, Susan E. Prockop, Richard J. O'Reilly
Journal: Blood (2013)
Prophylactic dexamethasone for radiation-induced bone-pain flare – Authors' reply
Authors: Edward Chow, Ralph M Meyer, Keyue Ding, Abdenour Nabid, Pierre Chabot, Philip Wong, Shahida Ahmed, Joda Kuk, A Rashid Dar, Aamer Mahmud, Alysa Fairchild, Carolyn F Wilson, Jackson S Y Wu, Kristopher Dennis, Michael Brundage, Carlo DeAngelis, Rebecca K S Wong
Journal: The Lancet Oncology (2016)
More postchemotherapy rheumatism.
Authors: I Michl, C C Zielinski
Journal: Journal of Clinical Oncology (1993)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1993.11.10.2051 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 8410132 More postchemotherapy rheumatism. I MichlxI MichlSearch for articles by this author , C C ZielinskixC C ZielinskiSearch for articles by this author https://doi.org/10.1200/JCO.1993.11.10.2051 PDF "More postchemotherapy rheumatism.." Journal of Clinical Oncology, 11(10), pp. 2051–2052© 1993 by American Society of Clinical Oncology
Study of vascular endothelial growth factor (VEGF) serial blood levels as predictor of response to chemotherapy
Authors: A. Irigoyen, J.-R. Delgado, P. Ballesteros, I. Rodriguez, E. Gonzalez, R. Luque, V. Conde, P. Belon, M. Sanchez-Moreno, J. Belon
Journal: Journal of Clinical Oncology (2004)

3146 Background: The molecular profile of a cancer may give information pertinent to response to chemotherapeutic agents. Vascular endothelial growth factor is a endothelial mitogen, survival factor and permeability inducer produced by many types of tumor cells. A rational approach is to study the sequential expression in peripheral blood of biomarkers during the treatment in order to select an individualized therapy. Methods: From February 2002 we have determined the serial levels of VEGF in the serum of cancer patients, with a life expectancy superior to 12 weeks, with a Karnofsky index superior to 60, which have received chemotherapy. The VEGF expression has been measured before the starting of treatment, after 2 courses, at the end of therapy, and when the disease progression was documented, using the enzyme-linked inmunosorbent assay technique ( Oncogene Research Products kits ). Until now 119 patients have completed 2 extractions Results: We have observed 2 groups according to the levels of VEGF in peripheral blood: The first group includes non small cell lung and gastric cancer, in which we have observed concentrations in the rank of 500 to 2000 pg/ml, and the second group is made up of ovarian, breast, colorectal, head and neck cancer where the lowest values are found over 100 pg/ml and the maximum does not reach 500 pg/ml. In most cases of lung cancer there is a relationship between the VEGF evolution and the response to treatment. The more advanced is the disease stage the bigger are the VEGF values at the first extraction. The VEGF values have been predictive of the disease evolution during the treatment in patients with gastric and ovarian cancer. VEGF confirmed their predictive value in case of discrepancy with computed tomography. Conclusions: The determinations of VEGF levels in peripheral blood before the chemotherapy and after the second course could predict the individual response to treatment in non small cell lung, gastric and ovarian cancer No significant financial relationships to disclose.
Human Tumor-Lymphocyte Interaction In Vitro. VI. Specificity of Primary and Secondary Autologous Lymphocyte-Mediated Cytotoxicity&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: F T Vánky, B M Vose, M Fopp, E Klein
Journal: JNCI Journal of the National Cancer Institute (1979)

A T-cell-enriched lymphocyte subset of samples from 15 tumor patients was tested for primary cytotoxicity against autologous tumor cell preparations and against 1–3 different allogeneic tumor cell preparations from biopsy material. Allogeneic cytotoxicity occurred in only 1 of 10 patients with autologous reactivity. The lymphocytes of 14 patients were cultured with autologous cells from biopsy material for 6 days. These lymphocytes killed autologous targets, but only 1 patient's lymphocytes were cytotoxic against 1 of the 4 allogeneic tumors tested. Cocultivation with allogeneic cells from biopsy specimens generated cytotoxicity toward the sensitizing allogeneic cells in 3 of 9 test combinations. In 2 of 3 instances the effectors were also active against the autologous tumor cells. Cytotoxicity in primary and secondary tests occurred thus only rarely against allogeneic targets. This indicated either the presence of individual tumor-related antigens on the cells from biopsy material or reflected the histocompatibility restriction of T-cell-mediated cytotoxicity.
Efficacy of endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing sarcoidosis in intrathoracic lymphadenopathy
Authors: Prashanth Shetty, Sanjay Agrawal, Jonathan Bennett
Journal: European Respiratory Journal (2013)

Background  Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS –TBNA) is a safe, effective and minimally invasive diagnostic tool in investigating intrathoracic lymphadenopathy. A previous meta-analysis found a diagnostic yield ranging from 54% to 93% (pooled diagnostic accuracy of 79%) in the detection of sarcoidosis.  Objectives  To evaluate the diagnostic yield of EBUS –TBNA in sarcoidosis performed in a single centre UK university teaching hospital.  Methods  We retrospectively analyzed patients who underwent EBUS-TBNA over a period of 3 years. We included patients with a final diagnosis of sarcoidosis who underwent EBUS-TBNA of intrathoracic lymphadenopathy and excluded patients with a final diagnoses of malignancy and tuberculosis.  Results  Between October 2009 and September 2012, 95 patients with a possible diagnosis of sarcoidosis who underwent EBUS-TBNA of intrathoracic lymphadenopathy were identified. Histopathological evidence of sarcoidosis or sarcoid like lymphadenopathy from EBUS-TBNA was identified in 73/95(76.8%); 22/95(23.2%) had normal or benign aspirate; 7/22 underwent further histological biopsy (6/7 confirmed diagnosis by cervical mediastinoscopy and 1/7 by video-assisted thoracoscopic surgery); 2/22 confirmed diagnosis by transbronchial biopsy and 1/22 by endobronchial biopsy; 12/22 were followed up in the clinic to determine the diagnosis. No significant complications reported.  Conclusion  Experience in our institution revealed a good diagnostic yield of 77%, which is consistent with the pooled accuracy of the recent meta-analysis and this is the largest data set published from a single centre in United Kingdom.
Abstract P047: Circulating Levels of the DDT Metabolite p,p'-DDE are Related to Prevalent Hypertension in the Elderly
Authors: Monica Lind, Samira Salihovic, Bert v Bavel, Lars Lind
Journal: Circulation (2012)

Background: Exposure to PCBs and dioxin to experimental animals increase blood pressure. We therefore investigated if circulating levels of persistent organic pollutants (POPs) were related to hypertension in a population-based sample. Methods: 1016 subjects aged 70 years were investigated in the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) study. Hypertension was defined as either use of antihypertensive treatment or blood pressure &gt; 140/90 mmHg. Twenty-one different POPs, including 16 PCBs, three pesticides (HCB, DDE and TNK), one dioxin (OCDD) and one brominated compound (BDE47) were analyzed by high-resolution chromatography coupled to high-resolution mass spectrometry (HRGC/ HRMS) at age 70. Results: 732 subjects (72%) showed hypertension. When the POPs were treated as continuous variables and adjusted for gender only, several of the PCBs with a low number of chlorine atoms (PCB74, 99, 105, 118 and 138) were related to prevalent hypertension. Also the OC pesticides, HCB, TNK, pp-DDE, and the brominated compound BDE47 were related to hypertension. The strongest of these associations were seen for pp-DDE (OR 1.35 for a SD change, 95%CI 1.17-1.56, p&lt;0.0001). Following further adjustment for serum cholesterol and triglycerides, BMI, smoking, education and exercise habits, only pp-DDE was still significant (OR 1.23 for a SD change, 95%CI 1.06- 1.43, p=0.006). Conclusion: In this cross-sectional analysis of an elderly population, high levels of circulating levels of pp-DDE were associated with prevalent hypertension, further strengthening the experimental findings that POPs might influence blood pressure.
A study of lavender and tea tree oils on postmenopausal FSH levels and hot flash severity
Authors: R. D. Cohn, C. Bornhauser, D. MacManus, M. Sadakane, W. Read
Journal: Journal of Clinical Oncology (2009)

1516 Background: Products containing lavender and tea tree oil have been linked to prepubertal male gynecomastia.(N Engl J Med 356:479–485) This implies that these products may be phytoestrogens, or plant products with estrogenic effects. Exogenous estrogens increase the risk of developing breast cancer and could counteract benefit from adjuvant hormonal manipulations in women with a history of breast cancer. We designed a study to determine the effects of lavender and tea tree oil on healthy postmenopausal women's FSH as a means to determine the estrogenic effect of both products. Hot flashes are a side effect of decreased endogenous estrogen, and in this study we used hot flash severity as an additional assay of estrogenic effect. Methods: Lavender lotion and tea tree oil products were generously donated by The Body Shop. Nine healthy postmenopausal women suffering from hot flashes were asked to apply lavender lotion and tea tree oil according to product directions for a week each, with a washout period in between. Participants were menopausal with baseline FSH &gt; 26 IU/mL. Serum FSH was obtained at baseline, after each lotion and after the washout period. Participants also recorded daily hot flash number and severity. Average daily hot flash severity was calculated for each patient during each period, with lotion use periods compared to Paired, 2-tailed T-tests were used to compare average hot flash severity for each participant as well as FSH values as compared to the baseline obtained before it. Results: Compliance was excellent. No significant differences were seen between time periods with either product for either measure. In no case did FSH dip to premenopausal levels. No indication of improvement in hot flash frequency or severity was seen. Conclusions: In our population, the lavender and tea tree oil products showed no estrogenic effects. This is similar to clinical trials of phytoestrogens, which as used by humans are not potent enough to affect FSH or hot flash severity. Both lotions can probably be used without increasing the risk of recurrent or de novo breast cancer. We intend one more study period in which participants will use a large daily amount of lavender lotion, again tracking hot flash severity and FSH. No significant financial relationships to disclose.
Outcomes with postoperative chemoradiation (CRT) in patients (pts) with gross residual disease (R2) following surgical resection of pancreatic adenocarcinoma (PA)
Authors: D. Moghanaki, A. Behbehani, A. Morgans, P. Salmon, E. E. Furth, W. Sun, B. J. Giantonio, J. M. Metz, E. F. Rosato, R. Whittington
Journal: Journal of Clinical Oncology (2008)

15628 Background: Despite extensive preoperative staging and advanced surgical technique, pts with resectable PA often have R2 resections because of unexpected invasion of retroperitoneal structures including celiac and/or superior mesenteric arteries. Prognosis for these patients is known to be poor, and our experience with postoperative CRT in these pts is reported. Methods: Between 1987–2005, 10 pts were identified with PA who underwent R2 resections and were treated with a course of postoperative CRT at our institution. Median age at date of surgery was 59 years (range 45–81). Median number of lymph nodes sampled was 13. Nine of 10 patients had introperative findings of celiac and/or superior mesenteric artery involvement. Seven tumors were located in the head of pancreas and 3 were distal. All tumors were either moderate or poorly differentiated. Median tumor size was 3.7 cm (range 2.0 - 5.0). 5FU-based CRT was delivered to the surgical bed and regional nodes with CT-based treatment planning utilizing 180 cGy daily fractions to a median dose of 5940 cGy with a range of 4,860–6,300. All patients after 1993 were treated with ≤5940 cGy. Results: All patients were deceased at time of analysis. Median survival time from date of surgery was 12.1 mo. (range 4.9 - 17.4) and from end of CRT was 9.6 mo. (range 2.8 - 14.3), respectively. Median survival for pN0 (n=3) vs. pN1 (n=7) was 13.0 (range 9.6–15.1) v 12.0 (range 4.9–17.4) months, respectively. Median survival time for pts treated with 6,300 cGy (n=3) vs ≤5940 cGy (n=7) was 17.2 (range 14.1–17.4) vs 12.0.(6.2 - 14.5) months. Conclusions: Patients with PA who have gross residual disease have poor OS despite aggressive postoperative CRT. Outcomes are similar to pts with locally advanced PA treated with definitive CRT. No significant financial relationships to disclose.
Peripheral muscle electrostimulation: Cardiovascular response in COPD patients and long term effects
Authors: Bruno-Pierre Dubé, Marilyn Houle-Péloquin, Poirier Claude
Journal: European Respiratory Journal (2011)

Conventionnal pulmonary rehabilitation (PR) suppose minimal active exercise. Because the ventilatory limitation, severe COPD patients are not always able to fully participate. Electrostimulation (ESM) of the peripheral muscles helps to prevent total unuse of the patients muscles and could aim to a complete PR program. The long term benefits of this intervention may be evanescent. The cardiovascular effects of ESM are not known in severe to very severe COPD patients.  We prospectively studied 9 COPD patients (3 females and 6 males, mean age of 65 y/o, mean FEV1 of 0,78 L (28%)) undergoing home-based peripheral muscles ESM. This latter consisted of 5 periods of 20 minutes, 5 times a week and for 3 weeks. Short and long term benefits were measured according to 6MWT and 1RM leg press test. Cardiac frequency (F) and arterial pressure (AP) were registered each 5 minutes during periods 1, 7 and 15.  F and AP did not show any significant fluctuations from beginning to end of the ESM period, and there is no difference between periods 1 and 15. 6MWT showed a mild but statistically significant improvement (232 to 244 m, p = 0,02). The 1RM leg press was also improved (192 to 209 p, p=0,004). After, 3/9 patients were able to complete a PR program. At one year, 6MWT and 1RM leg press test were below the baseline values. ESM was well tolerated by the patients, without complication.   Conclusion:  Home-based ESM program is a safe procedure and is not associated with significant change in F and AP, and an immediate impact was observed on 6MWT and 1RM leg press test. It could precede a complete PR program in selected severe to very severe COPD patients and be offered in a context of hospitalization.